RNS Number : 6312X
Acambis PLC
26 June 2008
Acambis Annual Information Update
Cambridge, UK and Cambridge, Massachusetts - 26 June 2008 - Acambis plc (Acambis or the Company) (LSE: ACM) announces that, in accordance with the requirements of Prospectus Rule 5.2 issued by the Financial Services Authority, and following publication of the Annual Report on 23 April 2008, the following information has been published or made available to the public since publication of the last Annual Information Update up to 31 May 2008, in compliance with laws and rules dealing with the regulation of securities, issuers of securities and securities markets.
For the purpose of this update, only references to the information are provided. Full copies of each item can be found at the locations specified below. The information referred to in this Annual Information Update was correct at the time it was published but may now be out-of-date.
1. Announcements made via a Regulatory Information Service
All documents listed below were published via a Regulatory Information Service on the dates indicated.
Date of publication: Title
10 August 2007 Blocklisting six monthly update
13 August 2007 Annual Information Update
17 August 2007 Notice of results
31 August 2007 FDA licenses Acambis' ACAM2000™ vaccine for protection against smallpox
06 September 2007 Goldman Sachs' holding in Company
18 September 2007 Acambis welcomes sanofi pasteur's dengue vaccine progress
21 September 2007 Goldman Sachs' holding in Company
24 September 2007 Goldman Sachs' holding in Company
25 September 2007 Acambis updates on strategy and reports important progress during six months ended 30 June 2007
25 September 2007 Acambis appoints Elizabeth Jones as Chief Financial Officer
28 September 2007 Goldman Sachs' holding in Company
02 October 2007 Goldman Sachs' holding in Company
03 October 2007 Directors' interest in shares - purchase of shares
03 October 2007 Directors' interest in shares - grant of options
05 October 2007 Directors' interest in shares - purchase of shares
08 October 2007 INVESCO's holding in Company
16 October 2007 Directors' interests in shares - grant of options
23 October 2007 Goldman Sachs' holding in Company
08 November 2007 Notice of Interim Management Statement
13 November 2007 Acambis announces global collaboration agreement with Sanofi Pasteur on leading West Nile vaccine
19 November 2007 Legal & General's holding in Company
22 November 2007 Q3 2007 Interim Management Statement
30 November 2007 Voting rights and capital
17 December 2007 Acambis concludes C. difficile vaccine formulation work on schedule and will commence proof-of-concept trial in 2008
31 December 2007 Acambis delivers ACAM2000™ doses to US Government and increases 2007 revenue expectations
03 January 2008 Acambis reports positive data from trials of universal influenza A vaccine
07 January 2008 Blocklisting six monthly return
07 February 2008 Goldman Sachs' holding in Company
14 February 2008 Acambis welcomes US Department of Defense's transition to ACAM2000 as its only smallpox vaccine
24 February 2008 Acambis initiates pre-clinical testing with herpes vaccine from Harvard Medical School
20 March 2008 Acambis extends Sanofi Pasteur licensing agreement on single-dose JE vaccine to India and Indian subcontinent
04 April 2008 Holding in Company (Legal & General)
23 April 2008 $425m, ten-year ACAM2000™ smallpox vaccine contract awarded to Acambis by US Government
23 April 2008 Placing and Open Offer
23 April 2008 Preliminary results for year ended 31 December 2007 and business update - 'A year of significant change and progress'
01 May 2008 Directors' interest in shares - grant of options and deferred shares
19 May 2008 First quarter Interim Management Statement
19 May 2008 Result of Placing & Open Offer
20 May 2008 Results of Extraordinary General Meeting
21 May 2008 Directors' interests in shares - purchase of shares
23 May 2008 Holdings in Company (Aberforth and HBOS)
29 May 2008 Additional listing
30 May 2008 Total Voting Rights
5 June 2008 Results of Annual General Meeting
5 June 2008 Acambis appoints Peter Allen as Non-executive Director
19 June 2008 Director's interest in shares - grant of options under US Employee Stock Purchase Plan
24 June 2008 Company Secretary change
Copies of the documents published via RNS may be obtained from the Regulatory News Service provided by the London Stock Exchange (http://www.londonstockexchange.com/en-gb/pricesnews/marketnews/) and any related documents are available at the UK Listing Authority's Document Viewing Facility, Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS.
2. Documents filed at Companies House
The Company has submitted filings to Companies House in relation to the appointment and resignation of directors, the allotment of shares, the adoption of new articles of association and prints of special resolutions passed at the Company's Extraordinary General Meeting on 20 May 2008 and Annual General Meeting on 5 June 2008.
Electronic copies of these documents can be purchased from Companies House via its website at www.companies-house.gov.uk, and hard copies can be obtained from Companies House, Crown Way, Cardiff CF14 3UZ.
3. Other documents publicly available
The Company's Annual Report for the year ended 31 December 2007 (published on 23 April 2008) can be found on the Company's website, as can the half-year results announcements and Interim Management Statements (IMSs), published on 25 September 2007 (half-year results), 8 November 2007 (third quarter IMS), 23 April 2008 (preliminary full-year results) and 19 May 2008 (first quarter IMS). The Company's website is www.acambis.com.
Copies of all documents referred to above are also available for inspection at the Company's registered office (Peterhouse Technology Park, 100 Fulbourn Road, Cambridge CB1 9PT) during normal business hours or by request from the Company Secretary. Further information regarding the Company and its activities is available at www.acambis.com.
Enquiries:
Sarah Gowing, Company Secretary
Lyndsay Wright, VP, Communications and Investor Relations
Tel: +44 (0) 1223 275 300
This information is provided by RNS
The company news service from the London Stock Exchange
END
AIUBXGDLCXDGGIL